Oscar Health is drawing fresh attention after two of its directors, David Plouffe and Jeffery H. Boyd, added shares on July 10. The insider buying wasn’t symbolic. It was coordinated. Both men acquired 14,134 shares each, according to Nasdaq filings. That’s not a coincidence. That’s a signal. The company is sitting on roughly $3 billion in cash and just posted a Q1 2025 earnings per share of $0.92, beating consensus by $0.09. Revenue jumped 42% year-over-year to $3 billion. Net margin came in at 1.22%. Return on equity hit 10.59%.
Oscar’s market cap is $3.79 billion. It trades at a price-to-earnings ratio of 53.27. The forward P/E is 20.16. Analysts are split. Barclays slapped an “underweight” rating on July 2 with a $17 target. Wells Fargo downgraded the stock to “underweight” on July 11 and cut its target to $10. Piper Sandler held neutral at $14. Raymond James dropped from “outperform” to “market perform.” The average target across the board is $14.92. The stock closed at $15.03 on July 14.
The company’s debt-to-equity ratio is 0.22. Operating cash flow stands at $878 million. Free cash flow is $870 million. Oscar has zero long-term debt. That’s rare. The firm pulled out of Medicare Advantage and trimmed its geographic footprint to focus on ACA plans. It now serves over 2 million members and holds top-three market share in several states. The +Oscar tech platform is gaining traction. The company says it’s building the operating system for value-based care.
Insiders own 25.11% of the stock. Thrive Capital, led by Josh Kushner, controls 24%. Institutional ownership is 75.7%. Assenagon Asset Management added 584,421 shares last quarter. Wealth Enhancement Advisory Services increased its stake by 61%. The stock is volatile. It’s had 58 moves greater than 5% in the past year. It dropped 12.7% last week after the Wells downgrade. It bounced 3.35% on July 14 after a surge in trading volume.
🚨 $OSCR INSIDER BUYING 🚨
Directors David Plouffe and Jeffery H. Boyd both added on the same day (10th of July). pic.twitter.com/jxE15NX2fv
— Alex Capital (@alexcapital01) July 15, 2025
Oscar is projecting $2.25 EPS by 2027. That’s a 45% compound annual growth rate. The PEG ratio is below 0.6. EV to free cash flow is 2. That’s cheap. But the market isn’t convinced. Exchange acuity is rising. Less healthy enrollees are signing up. Pricing may not cover costs. Policy risk is real. But insiders are buying. That’s the part that matters.
Disclaimer: Not financial advice.
Sources:
https://www.nasdaq.com/market-activity/stocks/oscr/insider-activity
https://finance.yahoo.com/news/oscar-health-inc-oscr-bull-213027246.html
https://www.timothysykes.com/news/oscar-health-inc-oscr-news-2025_07_14/
https://www.fool.com/investing/2025/07/03/why-did-oscar-health-crash-on-wednesday-and-is-thi/